Overview

This trial is active, not recruiting.

Condition pulmonary hypertension
Treatment bq-123
Phase phase 2
Sponsor Brigham and Women's Hospital
Start date February 1999
End date October 2010
Trial size 80 participants
Trial identifier NCT00759408, 1999-P-003126

Summary

The purpose of the study is is to determine the effect, on the lung circulation, of BQ-123, an investigational compound which is not approved by the FDA.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification pharmacodynamics study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
BQ-123
bq-123
6-120 µg/min

Primary Outcomes

Measure
To determine the contribution of endothelin to pulmonary vasoconstriction
time frame: one testing visit

Secondary Outcomes

Measure
To determine the contribution of endothelin to vasoconstriction in primary and secondary hypertension
time frame: one testing visit

Eligibility Criteria

Male or female participants from 18 years up to 85 years old.

Inclusion Criteria: - known diagnosis of pulmonary hypertension Exclusion Criteria: - hypertension due to other reasons (not pulmonary)

Additional Information

Official title The Role of Endothelin in Pulmonary Hypertension
Principal investigator Mark A Creager, MD
Description Endothelin levels are increased in patients with pulmonary hypertension. We wish to compare the effect of an endothelin antagonist on pulmonary hypertension due to a variety of causes.
Trial information was received from ClinicalTrials.gov and was last updated in May 2010.
Information provided to ClinicalTrials.gov by Brigham and Women's Hospital.